smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Location: Germany, Bavaria, Munich
Employees: 1-10
Total raised: $1.293322M
Founded date: 2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.05.2023 | Seed | $1.293322M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 25.05.2023 | smartbax Announces Seed Financing of €1.2 Million to Develop... | May 23, 2023 Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation... | htgf.de/en... |
| 23.05.2023 | m4 Award winner smartbax completes seed funding of EUR 1.2 m... | Munich-based biotech company and m4 Award winner smartbax, which develops next-generation antibiotic... | bio-m.org/... |
| 23.05.2023 | smartbax Raises €1.2M in Seed Funding | smartbax, a Munich, Germany-based biotech company developing antibiotics against multi-drug resistan... | finsmes.co... |
| 07.03.2022 | m4 Award winners on track for success | Three winners of the m4 Award pre-founding competition have been successful. The Munich-based start-... | bio-m.org/... |
| - | smartbax | “We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-d... | fastfounde... |